- Home
- ALX vs RLAY Comparison
ALX vs RLAY Comparison
Compare ALX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- RLAY
- Stock Information
- Founded
- ALX 1928
- RLAY 2015
- Country
- ALX United States
- RLAY United States
- Employees
- ALX N/A
- RLAY N/A
- Industry
- ALX Real Estate Investment Trusts
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALX Real Estate
- RLAY Health Care
- Exchange
- ALX Nasdaq
- RLAY Nasdaq
- Market Cap
- ALX 1.2B
- RLAY 576.1M
- IPO Year
- ALX N/A
- RLAY 2020
- Fundamental
- Price
- ALX $228.01
- RLAY $3.63
- Analyst Decision
- ALX Sell
- RLAY Strong Buy
- Analyst Count
- ALX 1
- RLAY 11
- Target Price
- ALX $125.00
- RLAY $18.40
- AVG Volume (30 Days)
- ALX 77.9K
- RLAY 1.6M
- Earning Date
- ALX 08-04-2025
- RLAY 08-05-2025
- Dividend Yield
- ALX 7.74%
- RLAY N/A
- EPS Growth
- ALX N/A
- RLAY N/A
- EPS
- ALX 7.72
- RLAY N/A
- Revenue
- ALX $219,892,000.00
- RLAY $7,679,000.00
- Revenue This Year
- ALX N/A
- RLAY $14.31
- Revenue Next Year
- ALX N/A
- RLAY N/A
- P/E Ratio
- ALX $30.12
- RLAY N/A
- Revenue Growth
- ALX N/A
- RLAY N/A
- 52 Week Low
- ALX $184.76
- RLAY $1.78
- 52 Week High
- ALX $251.63
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- ALX 61.13
- RLAY 63.22
- Support Level
- ALX $222.50
- RLAY $3.10
- Resistance Level
- ALX $231.23
- RLAY $3.75
- Average True Range (ATR)
- ALX 5.35
- RLAY 0.23
- MACD
- ALX 0.07
- RLAY 0.03
- Stochastic Oscillator
- ALX 91.91
- RLAY 84.42
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).